Newsroom

Press
Releases

2.22.2021
Aumolertinib Phase 3 Study Meets Primary Endpoint in First-Line Treatment for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
EQRx has disclosed topline results of its Phase III study of epidermal growth factor receptor (EGFR) inhibitor, aumolertinib, in the first-line setting.
1.11.2021
EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing | News | EQRx
EQRx has raised approximately $750 million to date to advance its mission of bringing new medicines to patients and healthcare systems around the world.
9.14.2020
EQRx Strengthens Team with Industry Leaders in Drug Development, Patient Access and Organizational Culture | News | EQRx
EQRx strengthens team with industry leaders Rona Anhalt, Christian Antoni, Eric Hedrick and Daniel Hoey. Sir Andrew Dillon joins as an EQRx advisor.
1.12.2020
EQRx Launches to Create Innovative Medicines at Dramatically Lower Prices for People, Healthcare Systems and Society » EQRx
EQRx announced today that it is launching to create novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems.